EP Patent

EP2614369B2 — Method for determining the suitability of inhibitors of human ezh2 in treatment

Assigned to Epizyme Inc · Expires 2025-05-28 · 1y expired

What this patent protects

Patent listed against tazemetostat-hydrobromide.

Drugs covered by this patent

tazemetostat-hydrobromide (TAZEMETOSTAT HYDROBROMIDE)

Patent Metadata

Patent number: EP2614369B2
Jurisdiction: EP
Classification: —
Expires: 2025-05-28
Drug substance claim: No
Drug product claim: No
Assignee: Epizyme Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.